Literature DB >> 24824461

Differentiated thyroid cancer incidentally detected by ¹⁸F-FDG PET/CT: patient's future in a hot-spot?

Silvia Morbelli1, Marcello Bagnasco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24824461     DOI： 10.1007/s00259-014-2794-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  16 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

Review 3.  Follow up approaches in thyroid cancer: a risk adapted paradigm.

Authors:  R Michael Tuttle; Rebecca Leboeuf
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

6.  Whole-body CT screening: spectrum of findings and recommendations in 1192 patients.

Authors:  Claudia D Furtado; Diego A Aguirre; Claude B Sirlin; David Dang; Stephan K Stamato; Patrick Lee; Farhad Sani; Michelle A Brown; David L Levin; Giovanna Casola
Journal:  Radiology       Date:  2005-09-16       Impact factor: 11.105

7.  Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas.

Authors:  Chandrakanth Are; John F Hsu; Ronald A Ghossein; Heiko Schoder; Jatin P Shah; Ashok R Shaha
Journal:  Ann Surg Oncol       Date:  2007-08-23       Impact factor: 5.344

Review 8.  Management of thyroid incidentalomas.

Authors:  Robert J Silver; Sareh Parangi
Journal:  Surg Clin North Am       Date:  2004-06       Impact factor: 2.741

Review 9.  The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery.

Authors:  Kyoungjune Pak; Seong-Jang Kim; In Joo Kim; Bo Hyun Kim; Sang Soo Kim; Yun Kyung Jeon
Journal:  Endocr Relat Cancer       Date:  2013-07-04       Impact factor: 5.678

10.  The increasing incidence of thyroid cancer: the influence of access to care.

Authors:  Luc G T Morris; Andrew G Sikora; Tor D Tosteson; Louise Davies
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568
View more
  2 in total

1.  Employing Bayesian approach to the intermediate risk categories of the Bethesda thyroid cytopathology reporting system: can FDG PET/CT find a strong enough evidence-base to be practised clinically as an adjunct?

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-09       Impact factor: 9.236

2.  Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.

Authors:  S Morbelli; G Ferrarazzo; E Pomposelli; F Pupo; G Pesce; I Calamia; F Fiz; A Clapasson; M Bauckneht; M Minuto; G Sambuceti; M Giusti; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2016-11-14       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.